核酸代谢酶水平可预测晚期和复发性结直肠癌的化疗效果。
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer.
机构信息
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji, Tokyo 193-0998, Japan.
出版信息
Asian Pac J Cancer Prev. 2022 Mar 1;23(3):1005-1011. doi: 10.31557/APJCP.2022.23.3.1005.
BACKGROUND
Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) predict the effects of fluoropyrimidine. However, the effects of FOLFOX therapy from the perspective of fluorouracil plus leucovorin (FL) remain underexplored. Hence, the relationship between mFOLFOX6 therapy (mFOLFOX6) and therapeutic efficacy was evaluated in patients with advanced/recurrent colorectal cancer (CRC).
METHODS
Correlations between TS and DPD and primary and metastatic lesions in recurrent CRC were analyzed. Univariate and multivariate analyses of TS and DPD in combination with response rate (RR), progression-free survival (PFS), and overall survival (OS) were performed.
RESULTS
A positive correlation between DPD and primary and metastatic lesions; correlations between TS and RR, DPD and RR, and PFS and OS; and significant differences for RR and DPD and TS, PFS and DPD, and OS and DPD were obtained.
CONCLUSION
Nucleic acid metabolizing enzymes in primary lesions can be used to predict mFOLFOX6 efficacy in patients with recurrent CRC.
背景
胸苷酸合成酶（TS）和二氢嘧啶脱氢酶（DPD）可预测氟嘧啶类药物的疗效。然而，从氟尿嘧啶加亚叶酸（FL）的角度来看，FOLFOX 疗法的效果仍未得到充分探索。因此，本研究评估了 mFOLFOX6 疗法（mFOLFOX6）与晚期/复发性结直肠癌（CRC）患者治疗效果之间的关系。
方法
分析复发性 CRC 中 TS 和 DPD 与原发性和转移性病变之间的相关性。对 TS 和 DPD 与缓解率（RR）、无进展生存期（PFS）和总生存期（OS）进行单因素和多因素分析。
结果
DPD 与原发性和转移性病变之间呈正相关；TS 与 RR、DPD 与 RR、PFS 与 OS 之间呈正相关；RR 和 DPD 以及 TS、PFS 和 DPD、OS 和 DPD 之间存在显著差异。
结论
原发性病变中的核酸代谢酶可用于预测复发性 CRC 患者接受 mFOLFOX6 治疗的效果。
Zotero 插件